On November 4, 2016 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported that three abstracts relating to the Company’s lead product candidate, rigosertib were accepted for presentation at the 58th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in San Diego, California, which takes place December 3-6, 2016 (Press release, Onconova, NOV 4, 2016, View Source [SID1234516294]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentations are listed below.

Combination Therapy Phase 2 Data
Abstract Number: 3167
Title: Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study
Session Name: 637. Myelodysplastic Syndromes — Clinical Studies: Poster II
Date: Sunday, December 4, 2016
Presentation Time: 6:00 — 8:00 PM PST
Location: Hall GH (San Diego Convention Center)
Presenter: Shyamala C. Navada, MD, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

Safety Analysis Summary for >500 Patients Treated with Rigosertib in Clinical Trials
Abstract Number: 2011
Title: Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Session Name: 637. Myelodysplastic Syndromes — Clinical Studies: Poster I
Date: Saturday, December 3, 2016
Presentation Time: 5:30 — 7:30 PM PST
Location: Hall GH (San Diego Convention Center)
Presenter: Guillermo Garcia-Manero, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Computational Analysis of Subgroup Data from Previous Clinical Trials
Abstract Number: 4324
Title: Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response
Session Name: 637. Myelodysplastic Syndromes — Clinical Studies: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00 — 8:00 PM PST
Location: Hall GH (San Diego Convention Center)
Presenter: Guillermo Garcia-Manero, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX